We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel

By LabMedica International staff writers
Posted on 03 Nov 2026

Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. More...

This uncertainty can be especially important for high-risk groups, including older adults, young children, and immunocompromised patients. A newly launched test offers laboratories a flexible panel for rapid respiratory pathogen detection from a single sample.

Roche has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the cobas eplex respiratory pathogen panel 3 (RP3). The test is designed for the automated cobas eplex system and allows up to five customizable panel configurations. This flexibility is intended to help laboratories tailor respiratory testing strategies to local disease prevalence and patient population needs.

The cobas eplex RP3 panel simultaneously detects up to 19 viral and bacterial targets from a single nasopharyngeal swab sample. It includes common pathogens such as influenza A virus, respiratory syncytial virus, and SARS-CoV-2, and adds Bordetella pertussis to broaden bacterial pathogen detection. The panel also includes updated influenza virus and SARS-CoV-2 assays intended to improve coverage of current and recently circulating strains.

The system uses an automated sample-to-answer workflow that requires less than one minute of hands-on preparation time. Results are delivered in less than two hours, and the test supports 24/7 availability. The clearance expands Roche’s respiratory portfolio, which includes singleplex and multiplex assays for respiratory viral and bacterial infections.

The new test expands the existing capabilities of the cobas eplex respiratory pathogen panel 2, which has not been cleared or approved by the FDA. The RP2 test is authorized for use by qualified laboratories under an Emergency Use Authorization. Roche noted that rapid and accurate respiratory results can help clinicians reduce additional tests and radiographs, unnecessary antibiotic use, and time to discharge.

"Timely and accurate respiratory testing in critical situations can guide life-saving interventions," said Dan Malarek, President and CEO, Roche Diagnostics North America. "The cobas eplex RP3 panel gives laboratories the range of testing choices they need with quick turnaround times that can make a difference in patient care."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.